CMS Open Payments · Program Year 2024
ViiV Healthcare Company
ViiV Healthcare Company reported $38,692,752.88 across General Payments, Research, and Ownership to 65,891 physicians and teaching hospitals across 66,926 transactions.
- $38.7M
- All-tracks total
- 66,926
- Transactions
- 65,891
- Recipients
- +$755.5K
- General Payments vs PY2023
ViiV Healthcare Company reported $38,692,752.88 across all CMS Open Payments tracks (General + Research + Ownership) to 65,891 physicians and teaching hospitals in Program Year 2024 - ranking #59 of 1,925 reporting manufacturers (0.3% of the all-tracks industry total); General Payments alone were $8,870,853.73, averaging $587.22 per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer viiv-healthcare-company ViiV Healthcare Company
$38.7M · #59/1,925 · 0.3% industry · PY2024
- TOT $38.7M
- RANK #59
- SHARE 0.3%
- TXN 66,926
- RCP 65,891
- CAT 6
- GEN $8.9M
- ΔGEN +$755.5K
- TOP1 1.8%
- PY 2024
Volume peers
Nearest volume peer: Alnylam Pharmaceuticals Inc. ($39.2M)
ViiV Healthcare Company sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
ViiV Healthcare Company's CMS-reported General Payments increased by $755.5K (+9.3%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: VIIV HEALTHCARE COMPANYPY2023: VIIV HEALTHCARE COMPANYPY2024: ViiV Healthcare Company. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $8,115,379.01
- PY2024
- $8,870,853.73
What the Data Shows for ViiV Healthcare Company
In Program Year 2024, ViiV Healthcare Company reported $38,692,752.88 in payments to 65,891 physicians and teaching hospitals across 66,926 individual transactions, an average of $578.14 per transaction and $587.22 per recipient. That total places ViiV Healthcare Company at rank #59 out of 1,925 companies in the CMS Open Payments database, representing 0.3% of all industry payments reported nationwide for the year.
Of the 6 general-payment categories charted below, "Compensation for Services Other Than Consulting" is the largest at $5.3M across 1,734 transactions, 59.5% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Across 6 types of general payments, ViiV Healthcare Company's largest category was "Compensation for Services Other Than Consulting" at $5.3M - 59.5% of General Payments.
ViiV Healthcare Company reports 6 general-payment categories - the top three are Compensation for Services Other Than Consulting (59.5%), Food and Beverage (19.9%), and Travel and Lodging (10.4%). The remaining 3 categories make up 10.1% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How ViiV Healthcare Company divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Compensation for Services Other Than Consulting | $5.3M | 1,734 | 59.5% |
| Food and Beverage | $1.8M | 61,598 | 19.9% |
| Travel and Lodging | $923.4K | 2,340 | 10.4% |
| Consulting Fee | $876.3K | 201 | 9.9% |
| Space Rental or Facility Fees | $22.8K | 10 | 0.3% |
| Education | $457.12 | 8 | 0.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $783,600.98 (8.8%) of $8,870,853.73 in this company's General Payments records across 9,870 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for ViiV Healthcare Company
The five named recipients with the highest reported General Payments from this company
- 1
Brian Joseph Beesley
$163,390.33 across 135 reported transactions
- 2
Tulika N Singh
$160,543.57 across 152 reported transactions
- 3
Zandraetta Lecea Tims-Cook
$160,271.14 across 167 reported transactions
- 4
Noah Jason Lee
$155,052.07 across 147 reported transactions
- 5
Gary B Blick
$144,343.87 across 104 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as ViiV Healthcare Company's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about ViiV Healthcare Company.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with ViiV Healthcare Company.
Showing 6 of 1,924 companies with CMS-reported payment data.
Exelixis Inc.
Spinal Simplicity, LLC
Boehringer Ingelheim International GmbH
Sanofi Pasteur Inc.
Alexion Pharmaceuticals, Inc.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.